Disease · MONDO_0018975
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Selumetinib 25 mg/m2 vs Placebo: deaths from any cause | 0 of 71 | 0 of 74 | 145 | NCT04924608 | Trial comparisons |
| Selumetinib 25 mg/m2 vs Placebo: serious adverse events | 10 of 71 | 9 of 74 | 145 | NCT04924608 | Trial comparisons |
| Lovastatin vs Placebo: deaths from any cause | 0 of 74 | 0 of 70 | 144 | NCT00853580 | Trial comparisons |
| Lovastatin vs Placebo: serious adverse events | 6 of 74 | 1 of 70 | 144 | NCT00853580 | Trial comparisons |
| Phase II Stratum 1 vs Phase II Stratum 2: Best Overall Response Rate (Strata 1 and 2) | 15 of 27 | 12 of 21 | 48 | NCT02285439 | Trial comparisons |
| Cohort A vs Cohort B: Number of Participants With Adverse Events | 20 of 23 | 21 of 22 | 45 | NCT02101736 | Trial comparisons |
| Cohort A vs Cohort B: deaths from any cause | 0 of 23 | 0 of 22 | 45 | NCT02101736 | Trial comparisons |
| Cohort A vs Cohort B: serious adverse events | 2 of 23 | 5 of 22 | 45 | NCT02101736 | Trial comparisons |
| Lapatinib vs Control: Assess the Level of ErbB2 Phosphorylation in VS. | 5 of 9 | 2 of 4 | 13 | NCT00863122 | Trial comparisons |
| N-Acetylcysteine Treatment vs Placebo: deaths from any cause | 0 of 5 | 0 of 5 | 10 | NCT04481035 | Trial comparisons |
| N-Acetylcysteine Treatment vs Placebo: serious adverse events | 0 of 5 | 0 of 5 | 10 | NCT04481035 | Trial comparisons |
| Stratum 1 vs Stratum 2: serious adverse events | 1 of 4 | 0 of 5 | 9 | NCT01365468 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018975/comparisons